Zacks Research Issues Negative Outlook for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, March 25th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings of ($0.19) per share for the quarter, down from their previous estimate of ($0.18). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.43) EPS.

A number of other research analysts also recently issued reports on ESPR. The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target for the company. JMP Securities reiterated a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Stock Performance

Shares of ESPR opened at $1.61 on Friday. The business’s 50-day moving average is $1.79 and its two-hundred day moving average is $2.07. The company has a market capitalization of $318.54 million, a P/E ratio of -2.52 and a beta of 1.04. Esperion Therapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $3.94.

Institutional Investors Weigh In On Esperion Therapeutics

Large investors have recently bought and sold shares of the company. Summit Financial LLC boosted its stake in shares of Esperion Therapeutics by 18.2% in the fourth quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 7,150 shares during the last quarter. Foundations Investment Advisors LLC boosted its stake in Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 9,872 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Esperion Therapeutics by 15.5% during the fourth quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 13,101 shares in the last quarter. Two Sigma Advisers LP raised its position in shares of Esperion Therapeutics by 0.4% in the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock valued at $7,956,000 after buying an additional 16,100 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Esperion Therapeutics by 15.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 123,896 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 16,404 shares in the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.